Floatz logo

CRA-027483

Exocrine Pancreatic Cancer

Pharmacyclics LLC.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

104 Active assets in the Exocrine Pancreatic Cancer cohort.

Asset / SponsorPhaseRating
Eloxatin
OHSU Knight Cancer Institute
Phase 2/3BBB
Irinotecan
OHSU Knight Cancer Institute
Phase 2/3BBB
FLUOROURACILUM
Northwestern University
Phase 2/3BBB
Capecitabine
Zhejiang University
Phase 2BB
Gdc-0449
OHSU Knight Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

CRA-027483 is also rated in:

pancreatic ductal adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →
pancreatic neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →